The demand for large quantities of high-quality supercoiled plasmid DNA (Sc-pDNA) has increased over the years due to its primary role in gene therapy. The current situation with Covid-19 has further increased the demand for AAV-based or mRNA vaccines, for which pDNA is the starting material. The platform purification process developed by Cytovance addresses the main challenges in large scale manufacturing of pDNA such as scalability, quantity and quality. In addition to this, Cytovance has developed pDNA analytics that are an important aspect of deciding the success of the manufacturing process.
In this webinar, viewers will learn about:
- Strain selection, plasmid optimization, media composition and fermentation conditions necessary to produce high quality supercoiled plasmid DNA
- Challenges in pDNA manufacturing and a platform process designed to address the bottlenecks in the large-scale purification of plasmid
- Significance of designing a process with quality as priority
- Importance of Platform assays and analytics for manufactured plasmid DNA material of various grades used for gene therapy